Redwire vs. Rocket Lab: Which Space Stock Is a Better Buy in 2026?

Rocket Lab is presented as the stronger 2026 space-sector investment after FY2025 revenue rose 38% to $601.8 million, versus Redwire's 10.3% increase to $335.4 million. Both remain loss-making and cash-flow negative: Rocket Lab posted a $198.2 million net loss and negative $321.8 million free cash flow, while Redwire lost $226.6 million with negative $190.8 million free cash flow. Rocket Lab's more than $2 billion backlog, Neutron rocket development and pending Iridium acquisition support its growth case, though its 53.1x P/S valuation, financing-related leverage and execution risks remain significant.

Analysis

RKLB’s valuation embeds a transition from a launch provider into a vertically integrated defense-space prime; that makes execution on Neutron, cadence, and any IRDM transaction financing more important than near-term revenue growth. At a roughly 10x relative sales premium to RDW, even a modest launch-delay, cost-overrun, or equity-financing surprise can drive severe multiple compression before the underlying demand thesis is impaired. The market is likely underpricing the capital-intensity feedback loop: delays extend cash burn, which raises dilution risk, which in turn increases the return threshold required on acquired assets.

RDW offers the cleaner contrarian setup if its margin inflection is independently confirmed. Its component exposure has less launch-vehicle binary risk and could benefit as satellite constellations, missile-defense architectures, and on-orbit servicing programs broaden the supplier base; however, weak controls and concentrated program exposure mean backlog is not equivalent to recurring revenue. Over 6-18 months, a credible remediation of reporting issues and conversion of backlog into gross-margin expansion could narrow the valuation gap materially without requiring RKLB’s ambitious execution path.

The near-term catalyst calendar is asymmetric: RKLB needs proof points every quarter to sustain its premium, while RDW needs only a few clean quarterly reports, cash-burn moderation, and contract conversion to reset skepticism. Verify the reported IRDM transaction structure, purchase price, financing commitments, and regulatory path before treating it as a standalone catalyst; without those terms, its accretion/dilution profile cannot be assessed. Falsify the RKLB-underweight thesis if Neutron milestones remain on schedule while launch cadence and space-systems margins accelerate without incremental equity issuance; falsify the RDW recovery thesis if gross margin reverses, working capital consumes cash, or a major customer program slips.

Key Decisions for Investors

• Prefer a 1-3 month relative-value position: long RDW / short RKLB in beta-neutral dollar amounts after confirming RDW’s next filing is timely and control-remediation language has improved. Target 15-25% relative outperformance; exit if RDW reports renewed margin deterioration or RKLB delivers a clean Neutron milestone plus financing that avoids material dilution.
• Do not add outright RKLB exposure at the current premium ahead of definitive IRDM deal documentation and the next Neutron schedule update. Reassess long entry only if pro forma leverage, share issuance, and expected cash runway demonstrate that the acquisition does not require another discounted raise within 12 months.
• For existing RKLB longs, buy 3-6 month downside protection around launch, guidance, and transaction-financing events rather than selling the core position. The principal risk is not demand erosion but a 20%+ de-rating from a single execution or dilution event; hedge sizing should reflect that gap-risk profile.
• Place RDW on a post-earnings long watchlist rather than pre-positioning aggressively. Upgrade only if gross-margin improvement is accompanied by lower cash use and customer/program diversification; a demonstrated path to materially lower cash burn is the catalyst most likely to move the stock from a backlog story to a valuation re-rating.